Table 2.
Inotuzumab ozogamicin‐related adverse events, (a) all grades in ≥4 patients (b) grades ≥3
| Adverse event, n (%) | Inotuzumab ozogamicin treatment | ||
|---|---|---|---|
| 1.3 mg/m2 (n = 3) | 1.8 mg/m2 (n = 10) | Total (n = 13) | |
| (a) all grades in ≥4 patients | |||
| Thrombocytopenia | 3 (100) | 10 (100) | 13 (100) |
| Leukopenia | 3 (100) | 9 (90) | 12 (92) |
| Lymphopenia | 3 (100) | 8 (80) | 11 (85) |
| Neutropenia | 3 (100) | 8 (80) | 11 (85) |
| Aspartate aminotransferase increased | 3 (100) | 8 (80) | 11 (85) |
| Anorexia | 3 (100) | 8 (80) | 11 (85) |
| Nausea | 3 (100) | 7 (70) | 10 (77) |
| Blood fibrinogen increased | 2 (67) | 7 (70) | 9 (69) |
| Alanine aminotransferase increased | 1 (33) | 6 (60) | 7 (54) |
| Blood alkaline phosphatase increased | 1 (33) | 6 (60) | 7 (54) |
| Hemoglobin decreased | 1 (33) | 6 (60) | 7 (54) |
| Malaise | 3 (100) | 3 (30) | 6 (46) |
| Blood bilirubin increased | 2 (67) | 4 (40) | 6 (46) |
| Headache | 2 (67) | 4 (40) | 6 (46) |
| Constipation | 1 (33) | 4 (40) | 5 (39) |
| Influenza | 1 (33) | 4 (40) | 5 (39) |
| Blood lactate dehydrogenase increased | 2 (67) | 3 (30) | 5 (39) |
| Fibrin D dimer increased | 0 | 5 (50) | 5 (39) |
| Hyperglycemia | 1 (33) | 4 (40) | 5 (39) |
| Stomach discomfort | 1 (33) | 3 (30) | 4 (31) |
| Fatigue | 0 | 4 (40) | 4 (31) |
| Hypercholesterolemia | 1 (33) | 3 (30) | 4 (31) |
| Hypokalemia | 2 (67) | 2 (20) | 4 (31) |
| Somnolence | 2 (67) | 2 (20) | 4 (31) |
| Epistaxis | 0 | 4 (40) | 4 (31) |
| Rash | 1 (33) | 3 (30) | 4 (31) |
| (b) grades ≥3 | |||
| Thrombocytopenia | 2 (67) | 5 (50) | 7 (54) |
| Lymphopenia | 0 | 4 (40) | 4 (31) |
| Neutropenia | 1 (33) | 3 (30) | 4 (31) |
| Leukopenia | 0 | 2 (20) | 2 (15) |
| Blood bilirubin increased | 1 (33) | 0 | 1 (8) |
| Hypokalemia | 1 (33) | 0 | 1 (8) |